source
- PhRMA pushes back as prescription drug spending continues to rise, according to STAT+ newsletterSTAT+ Health Care Inc. newsletter author Bob Herman reports on the growing concern that prescription drug spending is rising despite industry attempts to downplay it. The piece appears in the July…
- FDA doubts efficacy of Capricor’s Duchenne stem-cell therapy after Phase 3 missThe U.S. Food and Drug Administration said Monday that Capricor Therapeutics’ stem‑cell treatment for Duchenne muscular dystrophy failed to meet the primary goals of its Phase 3 trial, contradictin…